What one share of Dogwood Therapeutics holds
We are a pre-revenue, development-stage biopharmaceutical company focused on developing new medicines to treat pain and neuropathy. Following the closing of the Combination described below, we became the sole owner of Pharmagesic (Holdings) Inc.
Dogwood Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.72 |
|---|---|
| Cash and investments | $0.29 |
| Book value | $2.03 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$52.50 | — | — | — | $90.13 |
| 2021 | — | −$47.90 | — | — | — | $43.52 |
| 2022 | — | −$27.66 | — | — | — | $9.99 |
| 2023 | — | −$7.05 | — | — | — | $4.94 |
| 2024 | — | −$12.52 | — | — | — | −$7.60 |
| 2025 | — | −$7.13 | — | — | — | $2.52 |
Common questions about Dogwood Therapeutics
How much does one share of Dogwood Therapeutics earn?
Over the last 12 months, Dogwood Therapeutics lost $1.72 for each share.
Does Dogwood Therapeutics pay a dividend?
Dogwood Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Dogwood Therapeutics’s book value per share?
Dogwood Therapeutics’s book value is $2.03 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Dogwood Therapeutics have?
Each share of Dogwood Therapeutics has $0.29 of cash and investments, as of June 30, 2026.
Has Dogwood Therapeutics bought back shares?
Dogwood Therapeutics’s share count rose about 2426% from 2020 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.